Cytyc to Buy Digene for $77M; Cervical Cancer Diagnostics Will Be One Focus | GenomeWeb

NEW YORK, Feb. 19 - Sample preparation firm Cytyc will acquire diagnostics company Digene in a stock and cash deal worth $77 million, the companies said on Tuesday

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.